These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38443105)

  • 1. Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly-Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying.
    Parkman HP; Rim DS; Anolik JR; Dadparvar S; Maurer AH
    J Nucl Med Technol; 2024 Mar; 52(1):3-7. PubMed ID: 38443105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of GLP-1 receptor agonists use in diabetic patients diagnosed with delayed gastric emptying and their demographic profile.
    Kalas MA; Dang TQ; Galura G; Alvarado L; Dwivedi AK; Deoker A; McCallum R
    J Investig Med; 2023 Jan; 71(1):11-16. PubMed ID: 36198436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration.
    van Zuylen ML; Siegelaar SE; Plummer MP; Deane AM; Hermanides J; Hulst AH
    Br J Anaesth; 2024 Apr; 132(4):644-648. PubMed ID: 38290907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of gastric emptying in diabetes.
    Phillips LK; Rayner CK; Jones KL; Horowitz M
    J Diabetes Complications; 2014; 28(6):894-903. PubMed ID: 25047170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.
    Maselli DB; Camilleri M
    Adv Exp Med Biol; 2021; 1307():171-192. PubMed ID: 32077010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
    Werner U
    J Diabetes Complications; 2014; 28(1):110-4. PubMed ID: 23992745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide Delays Gastric Emptying in Patients with Type 2 Diabetes Mellitus but not in Those with Gastroparetic Conditions.
    Beti C; Stratmann B; Bokman G; Dreier J; Hauber M; Lee-Barkey YH; Fischer M; Knabbe C; Tschoepe D
    Horm Metab Res; 2019 Apr; 51(4):267-273. PubMed ID: 30690693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study.
    Ghazanfar H; Javed N; Qasim A; Sosa F; Altaf F; Khan S; Mahasamudram J; Jyala A; Kandhi SD; Shin D; Mantri N; Sun H; Hanumanthu S; Patel H; Makker J; Balar B; Dev A; Chilimuri S
    World J Gastroenterol; 2024 Jul; 30(26):3221-3228. PubMed ID: 39086638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control.
    Jalleh RJ; Jones KL; Rayner CK; Marathe CS; Wu T; Horowitz M
    Diabetologia; 2022 Dec; 65(12):1981-1993. PubMed ID: 36194250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management.
    Hiramoto B; McCarty TR; Lodhia NA; Jenkins A; Elnaiem A; Muftah M; Flanagan R; Chan WW
    Am J Gastroenterol; 2024 Jun; 119(6):1126-1140. PubMed ID: 38634551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.
    Thazhath SS; Wu T; Bound MJ; Checklin HL; Standfield S; Jones KL; Horowitz M; Rayner CK
    Am J Clin Nutr; 2016 Jan; 103(1):66-70. PubMed ID: 26607942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship Between Control of Glycemia and Gastric Emptying Disturbances in Diabetes Mellitus.
    Halland M; Bharucha AE
    Clin Gastroenterol Hepatol; 2016 Jul; 14(7):929-36. PubMed ID: 26717862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric electrical stimulation: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(16):1-79. PubMed ID: 23074486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal hormonal dysfunction in gastroparesis and functional dyspepsia.
    Khoo J; Rayner CK; Feinle-Bisset C; Jones KL; Horowitz M
    Neurogastroenterol Motil; 2010 Dec; 22(12):1270-8. PubMed ID: 20939851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.
    Little TJ; Pilichiewicz AN; Russo A; Phillips L; Jones KL; Nauck MA; Wishart J; Horowitz M; Feinle-Bisset C
    J Clin Endocrinol Metab; 2006 May; 91(5):1916-23. PubMed ID: 16492694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus.
    Schirra J; Leicht P; Hildebrand P; Beglinger C; Arnold R; Göke B; Katschinski M
    J Endocrinol; 1998 Jan; 156(1):177-86. PubMed ID: 9496247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.